Lana Daniele, Traini Chiara, Bulli Irene, Sarti Giorgia, Magni Giada, Attorre Selene, Giovannini Maria Grazia, Vannucchi Maria Giuliana
Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Research Unit of Histology and Embryology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Front Pharmacol. 2024 Aug 6;15:1451114. doi: 10.3389/fphar.2024.1451114. eCollection 2024.
The gut microbiota (MB), although one of the main producers of Aβ in the body, in physiological conditions contributes to the maintainance of a healthy brain. Dysbiosis, the dysbalance between Gram-negative and Gram-positive bacteria in the MB increases Aβ production, contributing to the accumulation of Aβ plaques in the brain, the main histopathological hallmark of Alzheimer's disease (AD). Administration of prebiotics and probiotics, maintaining or recovering gut-MB composition, could represent a nutraceutical strategy to prevent or reduce AD sympthomathology. Aim of this research was to evaluate whether treatment with pre- and probiotics could modify the histopathological signs of neurodegeneration in hippocampal CA1 and CA3 areas of a transgenic mouse model of AD (APP/PS1 mice). The hippocampus is one of the brain regions involved in AD. Tg mice and Wt littermates (Wt-T and Tg-T) were fed daily for 6 months from 2 months of age with a diet supplemented with prebiotics (a multi-extract of fibers and plant complexes, containing inulin/fruit-oligosaccharides) and probiotics (a 50%-50% mixture of and ). Controls were Wt and Tg mice fed with a standard diet. Brain sections were immunostained for Aβ plaques, neurons, astrocytes, microglia, and inflammatory proteins that were evaluated qualitatively and quantitatively by immunofluorescence, confocal microscopy and digital imaging with ImageJ software. Quantitative analyses demonstrated that: 1) The treatment with pre- and probiotics significantly decreased Aβ plaques in CA3, while in CA1 the reduction was not significant; 2) Neuronal damage in CA1 Stratum Pyramidalis was significantly prevented in Tg-T mice; no damage was found in CA3; 3) In both CA1 and CA3 the treatment significantly increased astrocytes density, and GFAP and IBA1 expression, especially around plaques; 4) Microglia reacted differently in CA1 and CA3: in CA3 of Tg-T mice there was a significant increase of CD68+ phagocytic microglia (ball-and-chain phenomic) and of CX3CR1 compared with CA1. The higher microglia reactivity could be responsible for their more efficient scavenging activity towards Aβ plaques in CA3 in comparison to CA1. Treatment with pre- and probiotics, modifying many of the physiopathological hallmarks of AD, could be considered an effective nutraceutical strategy against AD symptomatology.
肠道微生物群(MB)虽然是体内β淀粉样蛋白(Aβ)的主要产生者之一,但在生理条件下有助于维持大脑的健康。生态失调,即MB中革兰氏阴性菌和革兰氏阳性菌之间的失衡,会增加Aβ的产生,导致Aβ斑块在大脑中积累,这是阿尔茨海默病(AD)的主要组织病理学特征。给予益生元和益生菌,维持或恢复肠道MB组成,可能是一种预防或减轻AD症状病理学的营养保健策略。本研究的目的是评估益生元和益生菌治疗是否能改变AD转基因小鼠模型(APP/PS1小鼠)海马CA1和CA3区域神经退行性变的组织病理学特征。海马体是AD涉及的脑区之一。从2月龄开始,将转基因小鼠(Tg)和野生型同窝小鼠(Wt-T和Tg-T)每天喂食6个月,饲料中添加益生元(纤维和植物复合物的多种提取物,含有菊粉/果寡糖)和益生菌( 和 的50%-50%混合物)。对照组为喂食标准饲料的Wt和Tg小鼠。对脑切片进行Aβ斑块、神经元、星形胶质细胞、小胶质细胞和炎症蛋白的免疫染色,并通过免疫荧光、共聚焦显微镜和使用ImageJ软件的数字成像进行定性和定量评估。定量分析表明:1)益生元和益生菌治疗显著减少了CA3区的Aβ斑块,而在CA1区减少不显著;2)Tg-T小鼠CA1锥体层的神经元损伤得到显著预防;在CA3区未发现损伤;3)在CA1和CA3区,治疗均显著增加了星形胶质细胞密度以及胶质纤维酸性蛋白(GFAP)和离子钙结合衔接分子1(IBA1)的表达,尤其是在斑块周围;4)小胶质细胞在CA1和CA3区的反应不同:与CA1区相比,Tg-T小鼠CA3区CD68+吞噬性小胶质细胞(球链表型)和CX3CR1显著增加。与CA1区相比,小胶质细胞更高的反应性可能是其对CA3区Aβ斑块清除活性更高的原因。益生元和益生菌治疗改变了AD的许多生理病理学特征,可被认为是一种对抗AD症状的有效营养保健策略。